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Abstract 
Antibiotic resistance has become a global problem and the need to hinder its continuous spread 
due to inappropriate prescribing of antibiotics, overuse of antibiotics in livestock, and 
insufficient hygiene practices in hospital, global trade and travel is of utmost concern. Treating 
resistant infections have an effect on both the hospital and society. The absence of accurate 
diagnosis of clinical infections is a call for rapid evidence-based diagnostic tests to help 
clinicians better identify and target bacteria causing infections. The proposed tool, AMR-Diag 
seeks to fulfil the need in the reduction of AMR spread with faster and more accurate 
diagnostics.  
In order to validate the need and establish early feasibility for the development of ABR-Diag, 
we used primary data from exploratory discussions from both representatives from 
microbiology lab and team with proposed tool, secondary data from articles amd databases. 
We used the Business model canvas to create value for the company and the Value Proposition 
Canvas to create value for customers. 
Norway adopts the EUCAST guidelines whose diagnostic workflow takes up to 3-4 days 
before a patient can get appropriate treatment with antibiotics. However, the sequence-based 
diagnostic workflow on ABR differs from the current standard EUCAST disk testing.  AMR-
Diag has a competitive advantage over other diagnostic methods. Length of patient stay in 
hospital is a serious cost element.  
The cost of DNA sequencing is a major obstacle for the proposed tool, AMR-Diag, to become 
implemented. However, the cost of DNA sequencing is expected to continue to reduce. The 
proposed tool AMR-Diag is a leap forward in the fight against AMR and therefore should be 
given a chance to prove what it can do in this course. We therefore propose that the company 
uses Norway as its beachhead market, and joins forces with its partners and do political 
lobbying for Norway to take a leading role in combating AMR. 
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1. Introduction 
The World Health Organization (WHO) defines antibiotics as medicines used to prevent 
and treat bacterial infections. According to WHO, antimicrobial resistance (AMR) spread 
is a principal threat to global health, food security, and development. It is worldwide and 
can affect anyone of any age from less developed to developed countries. Although 
antibacterial resistance occurs naturally, antibiotic resistant bacteria increasingly emerge 
and spread due to inappropriate prescribing of antibiotics, their overuse in the livestock 
sector, and insufficient hygiene practices in hospital. Global trade and travel are also 
accelerating the spread misuse and overuse of antibiotics (D’Costa et al., 2011; WHO, 
2017). It is worth noting that it is the bacteria and not the individual that becomes resistant 
to the antibiotic (WHO, 2015a). While there is a widely recognized need for new 
antibiotics to address AMR, the number of companies undertaking Research and 
Development (R&D) in this area has decreased substantially with a corresponding 
decrease in both the development pipeline and number of approvals for new antibacterial 
medicines (Payne, Miller, Findlay, Anderson, & Marks, 2015). Several point-of-care 
diagnostic tests provide results within a shorter time frame of 1-4 hours but are not able to 
provide information about the antibiotic resistance profile of the infection (Dubouix-
Bourandy et al., 2011; Poritz et al., 2011; Zumla et al., 2014).  
The burden of deaths from antimicrobial resistance is estimated to sky rocket to 10 million 
lives each year by 2050, at a cumulative cost to global economic output of $100 trillion 
(O’Neill, 2016) and losses of $2.9 trillion (~0.16% of their GDP) in Organization for 
Economic Cooperation and Development (OECD) countries (OECD,2016) . In order to 
tackle antibiotic resistance, the World Health Assembly, adopts a global action plan on 
antimicrobial resistance, which outlines five objectives to achieve continual ability to treat 
and prevent infectious diseases with effective and safe, high quality medicines, used in a 
responsible way and available to all in need: 
• To improve awareness and understanding of antimicrobial resistance through 
communication, education and training; 
• To strengthen surveillance and research; 
• To reduce the incidence of infection through effective sanitation and hygiene; 
• To optimize the use of antimicrobial medicines in both human and animal health; 
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• To ensure sustainable investment in contesting antimicrobial resistance (WHO, 
2015b) 
In Norway, resistance to antibiotics is monitored by 3 systems; Norwegian Surveillance 
System for Communicable Diseases (MSIS), Norwegian Surveillance System for 
antimicrobial drug resistance (NORM), Norwegian Surveillance System for antimicrobial 
drug resistance - Veterinary Medicine (NORM-VET) (NORM, 2017). In accordance with 
WHO to fight antibiotic resistance, the Norwegian Ministry of Health and Care Services 
outlines the National Strategy against Antibiotic Resistance 2015-2020 (Service, 2015) whose 
principal goals are: to reduce the total use of antibiotics, to use antibiotics appropriately (only 
when needed), to increase knowledge of what motivates the development and spread of 
antibiotic resistance, to be a driving force in international and normative work to increase 
availability, appropriate use, and development of new antibiotics, vaccines and better 
diagnostic tools. Among the sector specific goals, the health sector has to ensure that by 2020: 
Antibiotic use in the total inhabitants is reduced by 30 percent, measured in DDD/1000 
inhabitants/day, as compared with 2012; Norway will be one of the three European countries 
that uses the least antibiotics on humans, measured in DDD/1000 inhabitants/day; Prescription 
of antibiotics will be reduced from an average of 450 prescriptions per 1000 inhabitants per 
year to 250 prescriptions per 1000 inhabitants per year; Prescription of antibiotics for 
respiratory infections will be reduced by 20 percent, measured in DDD/1000 inhabitants/day, 
compared to 2012; and finally, studies will be carried out on the burden of disease as a 
consequence of antibiotic resistance, as a consequence of possibly too little antibiotic use, and 
the effect of infection control measures (Service, 2015).  
Norway has a National system for surveillance, officially nominated National Reference 
Laboratories and a National recommendation or obligation for reporting to health authorities 
(Prevention & Control, 2013). The prevalence of antibiotic-resistant bacteria in Norway is 
quite low, relative to the rest of Europe. Staphylococcus aureus resistance to Methicillin is the 
most common type of antibiotic resistance predominantly in hospital patients, people with 
weak immune systems and the elderly. Bacteria with the resistance mechanism Extended 
Spectrum β-lactamase carbapenemases (ESBLCARBA) and bacteria resistant to all available 
antibiotics has been detected in Europe and there is fear that these infections might spread into 
the Norwegian Health Care System (NORM, 2017). IMP carbapenemase, Klebsiella 
pneumoniae carbapenemases (KPC), New Delhi metallo-beta lactamase, Oxacillinase (OXA-
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48) and Verona integron-encoded metallo-beta lactamase (VIM), are the five most common 
carbapenemases in Enterobacteriaceae (Prevention & Control, 2013). This form of ESBL-
resistance is the most concerning and there are few treatment options for these patients. 
However, factors such as; increased antibiotic use, travel, importation of food and spread of 
resistant bacteria in food production can change the situation in Norway (NORM, 2017).  
It is therefore of utmost importance to estimate the disease burden and associated costs relating 
to antibiotic resistance in Norway (Service, 2015). Antibiotic resistance leads to longer 
hospital stays, higher medical costs and increased mortality. In many clinical situations 
infections are not accurately diagnosed and, in the absence of an accurate diagnosis, clinicians 
prescribe antibiotics just to be on the safe side. This leads to increasing rates of AMR.  There 
is therefore, a crucial need to provide rapid evidence-based diagnostic tests to help clinicians 
better identify and target bacteria causing infections. Treatment should therefore only 
commence in patients when a bacterial infection has been accurately identified. The correct 
antibiotic should be prescribed following rapid identification of the micro-organism alongside 
its antibiotic susceptibility (Plüddemann et al., 2015).  
1.1 Priority Pathogens 
According to the WHO priority pathogens list for Research and Development (R&D) of new 
antibiotics, Acinetobacter baumannii, carbapenem-resistant; Pseudomonas aeruginosa, 
carbapenem-resistant and Enterobacteriaceae (Klebsiella pneumoniae, Escherichia coli, 
Enterobacter spp., Serratia spp., Proteus spp., and Providencia spp, Morganella spp), 
carbapenem-resistant, 3rd generation cephalosporin-resistant, have been placed into the 1st of 
3 priority groups: critical, high and low (WHO, 2017). Incidence of bacterial infections caused 
by ESBL producing bacteria are increasing in Norway (NORM, 2017). Resistance of S. aureus 
to methicilin (MRSA) remains a public health priority in Europe with some countries 
recording above 25% MRSA cases in 2016. Resistance is also seen in Vancomycin resistant 
enterococci (VRE) with 77 cases of VRE reported to MSIS in 2015, Multidrug resistance 
(MDR) as seen in tuberculosis with 3-12 cases treated annually in Norway (NORM, 2017) 
(ECDC, 2017).  
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Klebsiella pneumoniae 
Klebsiella pneumoniae is common in urinary tract, respiratory tract, skin and bloodstream 
infections. It easily spreads between patients in healthcare settings through hands of hospital 
personnel and is a frequent cause of hospital outbreaks, if proper prevention and control 
measures are not taken. Resistance traits are often acquired through plasmids. 
Klebsiella.  pneumoniae has a chromosomally encoded class A beta-lactamase which makes 
it resistant to aminopenicillins. Carbapenem resistance in K.  pneumoniae by a range of 
carbapenemases, which may confer resistance to virtually all available beta-lactam 
antibacterial drugs is an emerging public health threat. 
More than one third of the K. pneumoniae isolates reported are resistant to at least one of the 
antibiotic groups under surveillance (fluoroquinolones, third-generation cephalosporins, 
aminoglycosides and carbapenems) (ECDC, 2017). Although carbapenemase resistance was 
low in 2016, the majority of carbapenem-resistant isolates had additional resistance to the 
antibiotic groups under surveillance. Patients infected with multi-drug resistant K. pneumoniae 
with carbapenemase resistance have limited treatment options including combined therapy 
and use of antibiotics like colistin and others from polymixins group (ECDC, 2017).  
E. coli 
Although Escherichia coli is part of the normal intestinal flora in humans, it is commonly 
associated with bloodstream and urinary tract infections of community and healthcare origins 
in Europe.  Escherichia coli resistance is either as a result of mutations or acquisition of mobile 
genetic elements encoding resistance mechanisms such as production of ESBLs. Escherichia 
coli resistance is continually increasing in Europe with increased resistance to commonly used 
antibiotics. Isolates are reportedly resistant to at least one of the antibiotic groups under 
surveillance. Resistance to carbapenems in E. coli remains low (<0.1%) in the EU/EEA 
(ECDC, 2017).  
Acinetobacter species 
Acinetobacter species mainly cause healthcare-associated infections, such as pneumonia and 
bloodstream infections, and often result in hospital outbreaks if appropriate prevention and 
control measures are not implemented. Acinetobacter species can persist in the healthcare 
environment and are difficult to eradicate once established. The Baltic countries, Southern and 
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South-eastern European countries show a high resistance level of Acinetobacter species. In 
2016, most of the reported isolates indicated combined resistance to fluoroquinolones, 
aminoglycosides and carbapenems (ECDC, 2017). 
Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a non-fermenting gram-negative bacterium commonly found in 
aquatic environments in nature. It is an opportunistic pathogen and a major cause of infection 
in hospitalised patients with localised or impaired immune systems. It is a common cause of 
hospital acquired pneumonia, bloodstream and urinary tract infections.  
Carbapenem resistance and resistance to fluoroquinolones, aminoglycosides, some beta 
lactams and polymyxins is common in P.  aeruginosa in many European countries. As 
P. aeruginosa is intrinsically resistant to the majority of antimicrobial agents, combined 
resistance to multiple antimicrobial groups is further complicating treatment of serious 
infections. Resistance occurs through modified antimicrobial targets, exclusion of antibiotic if 
they enter the cell and reduced permeability and degrading enzymes preventing antibiotics 
from penetrating its outer membrane (ECDC, 2017). 
Methicillin Resistant Staphylococcus aureus (MRSA)  
In addition to health-care associated infections, increasing levels of community-associated 
MRSA are being reported worldwide. In 2016, as in previous years, large inter-country 
variations in MRSA percentages among invasive isolates of S. aureus were observed across 
Europe. Based on consistent laboratory reports between 2013-2016, the EU/EEA population-
weighted mean MRSA percentage has significantly declined (ECDC, 2017). In Norway, 
MRSA infections are registered as healthcare-associated (HA) for healthcare personnel or 
cases diagnosed due to a stay in hospital or nursing home without reported infection abroad, 
community-associated (CA) for cases diagnosed in the primary health care without 
hospitalisation or having worked in in a healthcare unit or reported infection from abroad, or 
Imported infection based on cases where infection acquired abroad or from unknown sources 
are reported. Between 20 and 40 per cent of the Norwegian population are colonised with S. 
aureus without symptoms. MRSA are resistant to all penicillin-derived antibiotics making 
treatment of MRSA infectionis  difficult. Staphylococcus aureus is one of the most common 
causes of infection in healthcare institutions (NORM, 2017). 
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1.1.1 Susceptibility Testing  
Upon administration of an antibiotic, resistant bacteria are able to thrive and multiply over 
susceptible bacteria which are killed or inhibited. This process of influence by an antibiotic is 
called selective pressure for the survival of resistant bacterial strains. Although some bacteria 
may be naturally resistant, others may become resistant through genetic mutation or acquired 
resistance from another bacterium (Gallo & Puglia, 2013).  
Currently, bacterial susceptibility can be measured by both phenotypic and/or genotypic 
methods. Phenotypic methods including disk diffusion or MIC determinants in which the 
minimum inhibitory concentration (MIC) value of an antibacterial agent of an organism is 
determined, predict measurable susceptibility and resistance, while genotypic methods predict 
resistance only. Zone inhibition by a very low concentration of the agent is considered more 
sensitive than one which is not inhibited even by a high concentration. The clinical criteria are 
based on pre-established breakpoints which objectively classify an organism as either resistant 
or susceptible (sensitive). The S-breakpoint is a concentration that separates sensitive from 
non-sensitive micro-organisms. It is expressed as S ≤ X mg/L (where X is a MIC value), and 
the concentration which separates resistant organisms from non-resistant (e.g. sensitive or 
intermediately sensitive) organisms is called the R-breakpoint and is expressed as R > Y mg/L 
(where Y may be the same or a higher MIC value than X). Bacteria are classiﬁed as resistant 
when their MICs are above the predeﬁned threshold. Antimicrobial susceptibility testing in 
the European Union is harmonised through EUCAST which decided to develop a disk 
diffusion test built on the Mueller Hinton medium with a confluent McFarland 0.5 inoculum 
(EUCAST, 2017; Kahlmeter, 2014).  
ESBL producing organisms have become multidrug resistant and their detection is not always 
evident in routine susceptibility tests. The difficulty in detecting such complex resistant 
phenotypes is a serious challenge facing clinical laboratories and have contributed to the 
uncontrolled spread of ESBL producing organisms and related treatment failures. Hence, there 
is a need for better detection of ESBLs in the clinical laboratory (Mohanty, Gaind, Ranjan, & 
Deb, 2010).  
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The ESBL E-test method using the cefepime-clavulanate strip is confirmed to be the best 
method so far, especially in AmpC beta-lactamase producing organisms (Mohanty et al., 
2010), with sensitivity of 98%, better than 83% sensitivity using cefotaxime-clavulanate strip, 
and 74% sensitivity using ceftazidime clavulanate strip (Stürenburg, Sobottka, Noor, Laufs, 
& Mack, 2004).  
The Vitek ESBL test has proven to be more reliable than the 2-disk test for the detection of 
ESBLs in E. coli and K. pneumoniae, the two species in which ESBLs are most common. The 
test also detects hyperproduction of the K. oxytoca beta-lactamase, a situation which leads to 
similar resistance levels to that in ESBLs (Sanders et al., 1996).  
However, these currently used routine methodologies are still associated with time delays and 
economic cost, especially for organisms that are difficult to grow. They are often accompanied 
by a need for further genetic characterization of isolates such as sub-typing and identification 
of resistance genes, often requiring the involvement of specialized or reference laboratories. 
This further adds to the cost and time delays, reducing the possibility of a timely response. 
Whole genome sequencing (WGS) methods have proven to be feasible for surveillance 
purposes, with high concordance when compared to phenotypic susceptibility testing for the 
prediction of antimicrobial susceptibility (Tyson et al., 2015; Zankari et al., 2013). Other 
genotypic methods include Single PCR, multiplex PCR, Realtime PCR and Ligation 
techniques (Prevention & Control, 2013). Previous feasibility studies to identify antimicrobial 
resistant genes have developed a web-based method, ResFinder that uses BLAST for 
identification of acquired antimicrobial resistance genes in whole-genome data with 100% 
identity to 1862 GenBank files (Zankari et al., 2012). Spectrometric identification uses 
MALDI-TOF for analysis (Prevention & Control, 2013). 
 
1.2 Description of “The Proposed Tool” (AMR-Diag) 
 
The continuous spread of antibiotic resistance is a global problem with incidence of infections 
with ESBL-resistant bacteria increasing in Norway in particular and worldwide in general. 
The dire need for accurate and real-time diagnosis of patients to minimize AMR spread has 
greatly motivated Associate Professor, Dr. Rafi Ahmad and his team who are working on 
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developing a sequence-based method to detect antibacterial resistance. The project AMR-
Diag, which has been recently funded by the Research Council of Norway (RCN), Better 
Health and Quality of Life (BEDREHELSE) programme. AMR-Diag is a joint Indo-
Norwegian researcher project on antimicrobial resistance, following up the bilateral agreement 
of Science and Technology between India and Norway, and the Memorandum of 
Understanding on health research between the Indian Council of Medical Research (ICMR) 
and the Research Council of Norway (RCN). This project got research funding from Norway 
and India  of 11 million NOK. and feasibility studies are ongoing to see to its realization. The 
proposed tool is a real-time sequencing-based method for detection of antimicrobial resistance 
in humans. The plan is blood and/or urine samples of patient is sent from hospital or primary 
health care to a microbiology (MCB) lab for  DNA extraction, followed by a culture 
dependent/culture independent DNA sequencing. Based on a machine learning approach, 
microbial sequences will be matched in real time with sequences in the customized in-house 
database to detect bacterial species and resistance type and feedback is sent to the Physician 
(discussion with Dr Rafi). 
 
1.3 Aim of the study 
As its main objective, this project sets to validate the need and establish early feasibility for 
the development of antimicrobial resistant (AMR)- Diagnosis. 
Secondary objectives: 
• How practical is it for the primary (municipal e.g. GPs, Old people’s home) and 
hospital health care professionals to use the proposed tool (AMR-Diag)? 
• Is AMR-Diag advantageous from a cost and time over current detection methods? 
• Determine the value potential of AMR-Diagnosis. 
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2. THEORY/BACKGROUND 
2.1 Competition  
The sequence-based method for detection of antibacterial resistance may face a lot of 
competition as there are already existing techniques (Pulido, García-Quintanilla, Martín-Peña, 
Cisneros, & McConnell, 2013) to detect antibiotic resistance as summarized in the table below. 
Table 1: methods used to detect ABR 
Methods Description/characteristics 
Culture media  
(EUCAST, 2017; Sanders et 
al., 1996; Stürenburg et al., 
2004) 
-Phenotypic methods used to determine both antibacterial resistance and 
susceptibility 
-Results take 3-4 days 
-High sensitivity for detecting antibiotic resistance 
-Highly standardized by CLSI and EUCAST 
-These methods usually require pure cultures for susceptibility testing to be 
performed 
-Examples; broth dilution, E-test, Disk Diffusion and Commercial systems 
(Vitek from BioMerieux, Microsan WalkAway from Siemens) 
PCR-based techniques 
(Bogaerts et al., 2013; 
Monteiro, Widen, Pignatari, 
Kubasek, & Silbert, 2012) 
-Genotypic method to determine resistance only 
-Carried out in a relatively short period of time 
-Rapidly provides information on antibiotic resistance 
-The presence of resistance genes may not always compare with phenotypic 
resistance 
Examples; 
-single multiplex real-time  
- Real-time Array-PCR for Infectious Diseases technology  
MALDI-TOF MS -The use of MALDI-TOF MS for the identiﬁcation of resistant strains based 
on differences in spectra is extremely rapid and highly automated 
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(Hrabák et al., 2012) -The results obtained using MALDI-TOF MS may not always directly 
compare with phenotypic resistance and differences between strains that are 
not related to resistance complicate the explanation of results. 
Microarray  
(Cohen Stuart et al., 2010) 
-Identify the presence of speciﬁc nucleic acid sequences using complementary 
oligonucleotides 
- Can detect thousands of different resistant genes in a single assay 
-Highly sensitive and specific 
-Results obtained may not always correlate with phenotypic resistance as 
there is no data on MIC values 
-Microarray technique may have limited ability to detect resistance in isolates 
harboring novel or uncharacterized mechanisms of resistance 
-Method no longer in use but is being implemented in Illumina’s Hi-Seq 
genome sequencers 
Microfluidics 
(Choi et al., 2013) 
-Make use of extremely small volumes of reagent and analyte for detection of 
antibiotic resistance 
-MIC values can be obtained 
-Automated with the potential for providing results extremely rapidly (3-
4hours) 
-Due to their small size, the chips used in these assays can be fused into 
portable devices, which may facilitate antimicrobial susceptibility testing at 
the point of care 
Whole Genome Sequencing  
(Snitkin et al., 2013) 
 
-Has the potential to predict resistant phenotypes 
-when used alone, sequencing may fail to predict resistance pattern if it has 
not been genetically characterized 
-Rapid sequencing of an entire bacterial genome 
-High cost of sequencing relative to other methods 
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2.2 Evolution of DNA sequencing costs 
The cost of sequencing a genome has witnessed great improvement over the years, with the 
evolution of sequencing technologies. The initial cost of sequencing at $100 million in the 
early 2000s using the Sanger sequencing was brought down to $10,000 later in the decade 
following the introduction of next generation sequencing methods like Illumina, 
Pyrosequencing, and SOLiD in the market. This cost evolution (Figure 1) is as a result of 
acquisition of more sophisticated instrumentation and it continues to decrease as more and 
more sequencing methods (third generation technologies) are introduced into the market 
(Wetterstrand, 2018). 
 
  
Figure 1: cost per genome (Wetterstrand, 2018) 
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2.3 Business Model  
A business model describes the rationale of how an organization creates, delivers and captures 
value. It can be best described through 9 basic blocks which are; key company partners, key 
activities, key resources, channels, value proposition, customer relationships, customer 
segments, cost structure, and revenue streams. These 9 basic blocks which form the business 
model canvas, cover four main areas of the business: the customers, the offers, the 
infrastructures, and the financial viability (Osterwalder & Pigneur, 2010). The success of any 
business idea is determined from both investor and customer perspectives. The entrepreneur 
must set out to answer the following questions: 
➢ Who are the customers to be satisfied? 
➢ What is the market size and trend? 
➢ What competition is there in the market already and what about newcomers? 
➢ What is the competitive advantage of the product or service? 
➢ How much financial funding is needed and how will the business idea generate profit? 
 
 
Figure 2: the Osterwalder business model canvas (Osterwalder & Pigneur, 2010)  
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Customer segments 
The customer segment block defines the diverse groups of people or organizations a company 
seeks to satisfy. Customers are an important component of any business. Lack of profitable 
customers will crumble a company in no time. The different types of customer segments 
include; the mass market, the niche market, the segmented, the diversified market, and multi-
sided platforms. In the mass market, the business model focuses on large group of customers 
with similar needs and problems. The niche market requires the value propositions to be 
delivered to the distinct needs of specific customer segments. The segmented market 
distinguishes market segments with slightly different needs and problems. The diversified 
market serves more than two unrelated customer segments with very different needs and 
problems. Lastly, the multi-sides markets concentrate on two or more interdependent customer 
groups. Both customer groups are important for the success of the business (Osterwalder & 
Pigneur, 2010).  
Value proposition 
The value proposition explains how a product or service solves customer’s problems or 
improves their solution. It gives reason why a customer should patronize a particular product 
and not another i.e benefits a company offers to customers. Value Propositions may be 
Innovative, representing a new offer or Habitual, comparable to an existing market offer, but 
with added features. Creating value for customers may involve one or several of the following; 
customization in which the customer has several options to choose from, price of product or 
service, newness, accessibility, performance, convenience/usability, design, status/brand, 
getting the job done and reducing the cost of product or service (Osterwalder & Pigneur, 2010). 
Channels 
This block describes how a company reaches out to its customers to deliver its value 
proposition. Distinguishing between Direct (Own) and Indirect (Partner) channels, any 
channel must cover 5 phases as illustrated in the table below; raising awareness among 
customers about a company’s   products and services which could be through adverts, 
promotions, evaluation whereby customers are able to evaluate a company’s Value 
Proposition over its competitors, allowing customers to purchase specific products and 
services, delivering a Value Proposition to customers and finally, depending on the product, 
providing post-purchase customer support.  
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Table 2: types and phases of channels (Osterwalder & Pigneur, 2010) 
 
 
As shown in the table above, an organization can choose between its own channels, partner 
channels, or both of them when reaching its customers. The different channels must be 
integrated in such a way to create a great customer experience while making profit. Partner 
Channels lead to lower margins, but they allow an organization to expand its reach and benefit 
from partner strengths. Owned Channels and particularly direct ones create both higher 
margins and operating costs (Osterwalder & Pigneur, 2010). 
Customer Relationships 
This block describes how a company communicates with specific customer groups. It must be 
clear what kind of relationship the company wants to establish with a particular customer 
segment ranging from personal to automated. Customer relationships are motivated by 
customer acquisition, retention and boosting sales. Amongst others, we have customer 
relationships including; personal assistance, self-service, automated services, co-creation and 
communities (Osterwalder & Pigneur, 2010). 
Revenue Streams 
This block describes the various ways a company makes money from the different customer 
segments. The revenue could either result from one-time customer payments called 
Transaction revenues, or Recurring revenues resulting from an ongoing payment to deliver a 
Value Proposition or provide post sales customer support. Revenue streams can be generated 
from asset sales, usage fee, licensing, subscription fee, brokerage fee, advertising and leasing 
or renting. The revenue created from each revenue stream depends on the pricing mechanism 
used; Fixed menu pricing; predefined prices based on static variables and dynamic pricing; 
Prices change based on market conditions (Osterwalder & Pigneur, 2010).  
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Key Resources 
The Key Resources block describes the most important assets required to make a business 
model work. It describes what is needed by a company to make value propositions. These 
resources can be classified into Physical, Intellectual, Financial and Capital resources.  
Physical resources include physical assets such as manufacturing facilities, buildings, 
vehicles, machines, systems, point-of-sales systems, and distribution networks. Intellectual 
resources like brands, proprietary knowledge, patents and copyrights, partnerships, and 
customer databases are difficult to develop but offer substantial value when fully created. 
Financial resources represent the monetary needs required to run the business. Human 
resources are critical in knowledge-intensive and creative companies. Every enterprise 
requires human resources (Osterwalder & Pigneur, 2010). 
Key Activities 
The Key activity building block describes the most important things a company must do to 
make its business model work.  Key activities are required to create and offer solutions to 
customer problems, reach markets, sustain communication with customers, and yield 
revenues. Like Key Resources, Key Activities vary according to business model types. They 
are grouped into Production, Problem solving and Platform/network. Production activities 
relate to designing, creating and distributing products in significant amounts and of great 
quality. Problem solving activities seek to find new solutions to customer problems. Platfrom 
activities relate to platform management, service provisioning, and platform promotion 
(Osterwalder & Pigneur, 2010). 
Key Partnership 
Many companies build up a network of suppliers and partners to optimize their business, 
reduce business risks and acquire resources. Four types of partnerships can be identified; 
strategic alliance between non-competitors, strategic partnership between competitors. Joint 
ventures to develop a new business and buyer supplier relationships to ensure reliable supplies 
(Osterwalder & Pigneur, 2010). 
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Cost structure 
Cost structure describes all relevant costs incurred to make a business model work. Costs can 
be incurred from creating and delivering a Value Proposition, sustaining Customer 
Relationships, and generating revenue, which are easily calculated from proper well defined 
Key Resources, Key Activities, and Key Partnerships. Every business model seeks to 
minimize cost and we can distinguish 2 classes of business model Cost Structures:  cost-driven 
and value-driven. Cost-driven business models focus on minimizing costs wherever possible. 
This approach aims at creating and maintaining the leanest possible Cost Structure, using low 
price Value Propositions, maximum automation, and extensive outsourcing. Value driven 
business models are more focused on creating value that cost implications. They create 
Premium Value Propositions with highly personalized services (Osterwalder & Pigneur, 
2010).  
Cost structures are characterized by fixed costs, variable cost, economies of scale and 
economies of scope. Fixed costs remain unchanged despite the amount of goods or services 
produced. Variable costs differ proportionally with the amount of goods or services produced. 
Economies of scale are cost advantages a business enjoys due to increasing productivity. 
Economies of scope are cost advantages a business enjoys due to a larger scope of operations 
(Osterwalder & Pigneur, 2010). 
 
2.4 Value Proposition Canvas 
The Value Proposition Canvas zooms into the details of two of the building blocks of the 
Business Model Canvas; Value Proposition and Customer Segment and helps in creating value 
for customers. The Value Proposition Canvas has two sides, with the Customer Profile which 
clarifies customer understanding. The particular customer segment from our business model 
is broken down into its jobs, pains, and gains and the Value Map which describes how we 
intend to create value for our customer(s). It breaks down our value proposition into products 
and services, pain relievers, and gain creators. A Fit is achieved between the two when one 
meets the other. Three kids of fit that can be identified; Problem-solution Fit, Product-Market 
Fit and Business Model Fit (Osterwalder et al., 2015).  
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- Value Map  
Products and Services: provides a list of propositions the company intends to offer its 
customers. Products and services could be tangible, intangible, digital or financial with 
relevance ranging from “nice to have” to “essential” (Osterwalder et al., 2015). 
Pain relievers: describes how the value proposition alleviate specific customer groups out of 
their pain. These could be things that annoy customers before, during, or after they are trying 
to complete a job or that prevent them from doing so (Osterwalder et al., 2015). 
Gain Creators: describes how products and services create gain for customers. Gain creators 
focus on those gains relevant to customers and where our products and services can make a 
difference (Osterwalder et al., 2015). 
- Customer Profile 
Customer jobs: describe what customers are trying to get done in their work and in their lives, 
as expressed in their own words. We distinguish 3 different jobs including functional jobs, 
social jobs and emotional jobs which range from insignificant to important depending on 
customer preference (Osterwalder et al., 2015). 
Pains: describe bad outcomes, risks, and obstacles related to customer jobs. Severity of the 
pain ranges from moderate to extreme (Osterwalder et al., 2015). 
Gains: describe the outcomes customers want to achieve or the concrete benefits they are 
seeking. Four types of customer gains can be identified including; required, expected, desired 
and unexpected gains. their relevance ranges from nice to have to essential (Osterwalder et al., 
2015). 
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Figure 3: Value Porposition canvas (Osterwalder et al., 2015) 
 
2.5 Market Segmentation 
Market segmentation is the process of splitting customers, or potential customers, in a market 
into different groups, or smaller subsets of consumers with similar taste, demand and 
preference. This means that, given the various needs of consumers, a strategic company is one 
which positions itself based on the abilities to serve the best and most profitable market 
segment; and different market segments require different market strategies. Considering the 
fact that not all individuals have similar needs, the overall aim of segmentation is to identify 
growth potential segments which can become target markets (Armstrong, Adam, Denize, & 
Kotler, 2014; McDonald, 2012).  
In a segmentation process, the build-up approach sees customers as different and then proceeds 
to identify possible similarities between them. The break down approach on the other hand is 
mostly used to segment consumer markets and sees customers to be identical and targets to 
identify groups which share particular differences. Segments are developed in the interaction 
between two or more parties. The segmentation model should be able to identify risk factors 
in a market and be able to adjust to these by being dynamic (Freytag & Clarke, 2001). 
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A Dynamic Interaction Segmentation model in Figure 4 regards the buyer's perception of their 
own needs and wants as an important variable of segment identification. Needs and wants are 
developed through interaction between buyer and seller with influence from the activities of 
the competitors and environmental changes. 
 
Figure 4: Dynamic interaction segmentation model (Freytag & Clarke, 2001) 
In order to segment a market: 
➢ customers in the different segments must have different preferences and needs 
➢ customers must have different ability and willingness to pay 
➢ the company must be able to reach out to the different customer groups 
 
 
 
 
 
 
 
 
 
 
Segment
Environment
Competitors
Seller
Buyer
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Table 3: market segmentation 
Segmentation base Brief description 
Business to business (B2B) 
➢ Stakeholders 
 
This segment involves customers such as the government, owners 
(shareholders), suppliers etc. 
➢ Geographics Physical location or region 
Business to customers (B2C) 
➢ Demographics 
 
Segments defined by measurable description of customers such as age, sex, 
socio-economics etc. 
➢ Geographics Segment with identifiable location to customers such as country, state, 
region, city etc. 
 
➢ Psychographic  
 
This segment is classified by a customer’s inner feelings and the tendency 
to behave in certain ways. It includes lifestyle, social or personal 
characteristics 
➢ Behavioral Segment classified by purchasing or consumption behaviour of the 
consumer 
 
2.5.1 Burden of antibiotic resistance 
Although antibacterial resistant infections are costlier to treat than susceptible infections, there 
is a scarcity of deﬁnitive cost evidence available to allow for a comprehensive study of the 
economic burden of this resistance (WHO, 2014). From a medical, social, and economical 
viewpoint, bacterial resistance is of great concern, becoming common in healthcare 
institutions and often resulting in treatment failure, thereby, implying an added burden on 
healthcare costs. Assuming an average antibiotic cost of $20, the total societal cost of 
antibiotic resistance (SCAR) attributable to each ambulatory antibiotic prescription in the US 
would increase antibiotic costs by 65 % (with hospitalization cost contributing the highest) 
when combined with antibiotic costs paid by patients or payers (Michaelidis et al., 2016).  
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In the event of an outbreak, fatal infectious diseases are both scary and expensive to deal with. 
Countries can choose one of three following options to pay for ABR; first, wait until there is 
a problem and then try to solve it as in the case of disease outbreaks. Second, recognize that 
prevention is better than cure and individually invest in the tools needed to fight resistance. Or 
third, by working together and jointly paying for global public goods to efficiently and 
effectively avoid large-scale outbreak of untreatable infections (Resistance, 2016). In order to 
help policy makers and healthcare professionals to make appropriate health decisions, there is 
a need to measure the economic burden of ABR which is directly linked to disease burden. 
Some factors affecting the quantification of economic burden of ABR  include; increasing 
prevalence of antibiotic resistance, effects of unavailability of effective antibiotics in common 
medicines such as surgery, transplant and chemotherapy, and Effect of antibiotics on national 
income, labor supply and economic growth (Gandra, Barter, & Laxminarayan, 2014).  
The business model for antibiotics is not balanced by the opportunity to make attractive profit. 
The developer gets a very low return for creating something which greatly benefits the society. 
Without more attractive returns for investors, the number of new antibiotics reaching the 
market will continue to decrease and antibacterial resistance will continue to spread. There 
needs to be a rebalancing between the value to society and the value to investors, as without 
that, investment will continue to decline, and the long-term impact will be a huge societal cost. 
Empiric therapy results in needless courses of antibiotics prescribed to patients who do not 
even have a bacterial infection. This model has led to increasing resistance, unnecessary side 
effects and negative impact on the human microbiome. The development and use of simple, 
cheap, efficient and accurate rapid diagnostics to identify the infecting pathogen and its 
susceptibility profile could hinder resistance worsened by empirical therapy.  Low cost, simple 
or no instrumentation and ease of use are crucial to global utilization of diagnostic tests (Payne 
et al., 2015). Some tests include:  Influenza Breath POCT; a Community-Associated Lower 
Respiratory Tract Infection test, a Nucleic Acid-Based Ventilator-Associated Pneumonia test, 
The Xpert® Carba-R, Cepheid Xpert MRSA/SA SST, Curetis Unyvero Pneumonia P50 Test 
and Bioﬁre Filmarray Respiratory Panel (Dubouix-Bourandy et al., 2011; Payne et al., 2015; 
Poritz et al., 2011; Zumla et al., 2014).  
The antibacterial drug market is forecast to rise from about $27.1 billion in 2015 to $35.6 
billion in 2022. This is as a result of market drivers including growing use of new diagnostic 
tests, increased geriatric population; challenges including high RnD cost, uncertain regulatory 
policies, and rapid emergence of antibacterial resistant strains; market trend is an increase in 
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the demand for antibiotics. Increasing incidence of pneumonia, blood stream infections, and 
urinary tract infections (UTI) are anticipated to foster the usage of carbapenems class of 
antibiotics (Research & Markets, 2015). The impact the present diagnostic model (sequence-
based method) has on development and spread of resistance (on bacteria type) will be 
important for such estimations. The cost incurred by such diagnosis resulting in fewer sick 
individuals and a reduction in the spread of infection will therefore, be a good investment. 
Diagnostic testing helps physicians or GPs to differentiate viral from bacterial infections and 
determine the susceptibility of agents involved (Cecchini & Lee, 2017) in order to decide what 
antibiotic works best for what infection as shown in the diagram below: 
 
 
 
 
Figure 2: Use of diagnostic tests 
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2.6 SWOT Analysis 
This is a tool used to analyse a business or project with reference to its internal factors 
(strengths and weaknesses) and external factors (opportunities and threats. It is aimed at 
determining whether a business or project should continue, stop or be redesigned.   or not a 
project or business should be established. 
 
Figure 5: SWOT Analysis for sequence-based method 
 
 
  
• there is a dire need for diagnostic test
•can be patented
•available funding from the Innovation Norway
• rarity of product
strengths
•small market size in Norway
•concept in progress
• limited flexibility in pricing
•genotypic method with reistance only but no measurable 
susceptibility
weaknesses
•key partnership with diagnostic labs
•ability to expand market opportunities
• growing spread of ABR
• rarity of sequence based diagnostic methods
opportunities
threats
Competition from PCR based methods and culture on selective 
media. 
Economic risks 
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3. Materials and Method 
Data Collection: using a deductive inductive approach (Greener & Martelli, 2015), we 
conducted primary data from an exploratory interview with Dr Anders Bredberg of the 
Sykehuset Innlandet, Microbiology Department at Lillehammer who gave us an insight on the 
common hospital infections and the antibiotic resistance workflow, explaining what happens 
at each stage when a patient in down with an infection. A discussion with Dr Rafi Ahmad gave 
us the description of the proposed tool. We also collected secondary data by article search 
from the internet and the Library. We also used the Osterwalder business model canvas to 
formulate a business plan for our sequence-based technology. 
Search strategy: We searched for review articles published in English in PubMed, Google 
Scholar and WHO publications with the terms “antibacterial resistance”, “antibiotic resistance 
in humans” “cost of antibiotic resistance” “burden of antibiotic resistance”, etc for the period 
of 2013-present. From the review article references, we were able to get primary articles of 
importance which were then used in our study. 
In order to determine carbapenemases in Enterobacteriaeceas, a search was done on NCBI. 
Using SRA database to search for “carbapenemase”, E. coli and Klebsiella were each selected 
from top organisms. Results were sent to the RunSelector and viewed as an expanded 
interactive table. By clicking on each of the Biosamples, we were able to determine which 
contained carbapenemase or not. The tables (for each of the bacteria) were then downloaded 
to Excel. Search was performed on 21/01/2018. From the excel file (appendix2), highlighted 
samples are non-carbapenemases.  
Using NCBI and “Nucleotide” database, search words used for the number of nucleotide 
sequence for E. coli, Acinetobacter, Klebsiella and Psuedomonas in ESBLs classes B and C 
on included “IMP carbapenemase, VIM (metallo-β-lactamase), NDM-1 (New Delhi metallo-
β-lactamase) and CMY beta-lactamase”. For each of these classes of ESBL, four groups of 
bacteria (E. coli, Klebsiella, Psudomonas and Acinetobacter spp) were used for the nucleotide 
sequence by clicking the “top organisms” on the right-hand side of the searches. Also, 
GenBank information given was used to determine the source or host of the bacteria by 
searching up indicated articles on PubMed.  Search was performed on 25/01/2018 (appendix 
1).  
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4. RESULTS AND DISCUSSION 
4.1 Diagnostic Workflow 
From our onsite visit and interview, we noticed the following workflow for the diagnosis and 
treatment of ABR from when patients engage General Practitioners/hospitals to when patients 
are treated as shown in the figure below. 
 
Figure 6: Antibiotic resistance diagnostic workflow 
 
In Primary Health Care, when a patient visits the General practitioner (GP), their blood sample 
is collected and rapidly a C-reactive protein (CRP) test is run to differentiate bacterial from 
viral infections. High levels of CRP are indicative of bacterial infection and patient could be 
prescribed with antibiotics in case ABR is suspected. The blood and/or wound samples from 
the GP and hospital healthcare are sent to the Microbiology Laboratory or Fürst Lab for culture 
and resistance testing. Following EUCAST guidelines, samples are cultured on Mueller 
Hinton Agar with horse blood. Culture takes about a day and then susceptibility testing is 
done, depending on the type of pathogen found, which also takes one day. PCR-based 
technology is then used to determine resistance within a few hours. Depending on ABR test 
results, the patient is then treated with appropriate antibiotics (interview with Dr. Anders). 
This just goes to show the long waiting times involved in using the standard EUCAST 
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antibacterial susceptibility testing methodology taking at least three days to have results. The 
standard process of culture and susceptibility testing generally takes 3-4 days and sometimes 
even more than a week, meanwhile, many patients are empirically treated with antibiotics. 
Although it is faster, cheaper and more clinically effective for an individual patient to be 
treated with antibiotics empirically. However, for the community and future populations, 
targeted therapy which reduces the potential of resistance may ultimately cure more infections 
and save more lives  (Cecchini & Lee, 2017; Payne et al., 2015). Norway like most European 
countries adopt the EUCAST guidelines for susceptibility test. Use of rapid diagnostic tests is 
limited. Rapid diagnostic tests are only available nationwide in 40% of OECD countries 
(OECD, 2016).  
4.2 Workflow of sequence-based diagnostics of antibiotic-
resistance 
1. Primary health care or hospital to take blood sample/swabs from patient with infection 
2. DNA isolation by molecular biology lab 
3. DNA sequencing done by a molecular biology lab 
4. DNA sequence continuously sent by internet to the company´s server 
5. Sequence analysis by the company´s algorithms and database 
6. Feedback of the results to the health care professional (or patient) 
7. Possible continuous feedback to NIPH for surveillance purpose 
With the current diagnostic workflow following EUCAST guidelines, the AMR-Diag 
sequence-based method still fits in as it involves Primary health care or hospital collecting 
blood/urine/swabs from patients and sending to the microbiology lab for DNA extraction 
followed by sequencing. Samples can also be sent to the a molecular lab for DNA extraction 
and sequencing analysis. This means less work for the MCB lab since the sequencing is culture 
free and will only take a couple of hours. Unlike the EUCAST guideline method, AMR-Diag 
will provide digital results which can be stored and used further analysed. Although we expect 
the cost of sequencing to become cheaper with time, AMR-Diag in routine laboratories is 
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expensive knowing that the cost of sequencing is more than that of EUCAST disk diffusion 
test.  
4.3 Future implications of a sequence-based approach for 
diagnostics 
The method has a potential for being a disruptive innovation. Today we operate the good old 
workflow with doctors/nurses taking blood samples/swabs and sending them to a diagnostic 
lab (private or public) for diagnosis. It is possible to see this set into a more distributed system 
contrary to the todays centralised system. DNA isolation has been automated and can in the 
future be part of the DNA sequencing instrument or closely integrated with such an instrument. 
This is what is called the “black box principle”, patient sample in and result out. It may be 
possible to do the testing without lab expertise. This can open up the possibility for primary 
health care to do the operation without the help of a centralised lab, although the primary 
health care professional will need to send the data to the company for analysis. But this will 
in practise be just linking up to internet and feeding the digital data automatically to the 
company and getting the digital result back. The feeling will be of a local diagnostic procedure.  
The consequence of this thinking is that hospital healthcare will be important especially in the 
beginning to get the method implemented in the current workflow. However, primary health 
care will be crucial for the future success of the company. Most likely, the future revenue 
stream will mainly come from primary health care professionals. It is even possible to see a 
private market opening up, where the patient or relatives use a “drive-in” test center to get a 
quick diagnosis, a second opinion or monitor the treatment of the disease. 
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4.4 Can sequence-based testing be reliable? 
The nucleotide sequence search gave the following results summarised in Table 4 (from 
appendix 1) which are indicative of the total number of sequences that have been studied up 
till the point when search was conducted. This shows only a small number of sequences 
Enterobacteriaeceae, Acinetobacter and Pseudomonas species in ESBLs and therefore require 
more sequences yet to be studied or identified. 
Table 4: Number of nucleotide sequence for E. coli, Acinetobacter, Klebsiella & Psuedomonas 
in ESBLs (B&C). 
IMP carbapenemase 
-   Klebsiella spp 931 
-   E coli 49 
-  Pseudomonas spp 73 
-  Acinetobacter spp. 21 
NDM-1 (New Delhi metallo β lactamase) 
- E coli 337 
- Klebsiella spp. 81 
- Pseudomonas spp. 41 
- Acinetobacter spp. 31 
VIM (Verona integron metallo β lactamase) 
- Pseudomonas spp. 793 
- Klebsiella spp. 89 
- Acinetobacter spp. 27 
- E coli 14 
CMY (cephamycin hydrolysing) 
E coli 168 
Klebsiella spp. 44 
 
Summarising the data on appendix 2, we were able to determine the number of carbapenemase 
Biosamples from the 2 Enterobacteriaeceae (E. coli and Klebsiella) as shown in Table 5 
below. Out of a total of 235 runs from 218 E. coli sequences and 179 runs from 141 Klebsiella 
species, 166 and 153 are carbapenemase producing organisms respectively while only a 69 E. 
coli and 26 Klebsiella species and non carbapenemases. This therefore implies an increase in 
carbapenemases resistance which is a call for concern needing action. This is also indicative 
of the fact that the sequence based method has the ability to precisely identify the infectious 
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bacteria and possible resistance genes since it will be compared to already known sequences 
in the database in real time.  
Table 5: carbapenemase in Enterobacteriaeciae  
Enterobacteriaeciae No of sequences No of runs Carbapenemase Non-carba 
E. coli 218 235 166 69 
Klebsiella 141 179 153 26 
     
 
In order to make the business idea sustainable therefore, there is a need for NIPH to incentivise 
this method in order to make it affordable for the common populations. Although kick starting 
in Norway, after evaluating the performance of the method, it could extend its market to 
neighbouring countries and worldwide. Continuous search in the public database since new 
genomes are constantly being sequenced and published, and updating the proposed sequence 
tool will enable the sustainability of this business idea.    
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4.5 Creating value for the business 
  
Table 6: Osterwalder format business plan for sequence-based for detection of AMR 
Key Partners 
-Research Council 
of Norway (RCN) 
-Bedrehelse 
-Indian Council of 
Medical Research 
(ICMR) 
-Fürst Lab 
-Lillehammer 
Microbiology lab 
-Inland Norway 
University of 
Applied Sciences 
 
Key Activities 
-Detection of antibiotic 
resistance 
-Storage of results 
-Provide education and 
training on use of the 
technology 
-Sharing results with 
health units 
-Development of 
sequence-based method 
-Research and 
Development 
Value Proposition 
-Faster method for 
ABR detection 
(culture-free 
sequence-based) 
-Affordable ABR 
diagnostic method 
-Convenient method 
to be used by primary 
health care and 
hospital health care 
professionals 
-Data storage and 
sharing 
Customer Relationship 
-E-mails 
-Direct contact 
-Personal assistance 
-Automated service 
-Reference labs/groups 
Customer segments 
-NIPH 
-Primary health care 
-Hospitals acute dept. 
-Diagnostic labs 
-Nursing Homes 
-General Practitioners 
Key Resources 
-Infrastructure 
-Sequence database 
-Search algorithms 
-Competence in 
sequence-based 
diagnostics 
 
Channels  
Direct Channel 
-own sales force 
Indirect channel 
-through partners (GPs and 
diagnostic labs) 
 
Cost Structure  
Investment cost 
Research and development cost 
Labour cost 
Cost of storage of results 
Revenue Streams 
Cost of sequencing 
Sharing of results in the database 
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We segmented our market using business to business (B2B) as follows: 
Geographical  
Since the company setup for the sequence-based technology is in Norway, it will be beneficial 
to the company to first gain the market here in Norway and easily correct functional errors in 
the methodology before expanding it to other Scandinavian countries, rest of Europe and the 
rest of the world. Therefore, in order not to risk drowning the product through lack of 
differentiation or go too narrow and end up with few numbers we could use the beachhead 
strategy. Norway can be the beachhead to reach international markets. Norway due to its 
position of having few AMR cases can also be a leading star in developing new strategies to 
combat AMR. 
Stakeholders 
➢ Norwegian Institute of Public Health (NIPH): these are the policy makers 
responsible for knowledge production and regular evaluations for the health sector, 
providing knowledge about the health status in the population, influencing factors and 
how it can be improved. The NIPH has amongst its four divisions, the division of 
Health Services which provides a knowledge base for decision makers at all levels in 
the health care services, from central government to the municipal health service 
(NIPH, 2017). They can easily influence the implementation of the sequence-based 
method in use. 
➢ Diagnostic Laboratories: these are designated laboratories to carry out antimicrobial 
resistance test. This group of customers need to be convinced of the efficiency and 
convenience the sequence-based method has over the standard culture media.  
 
 
 
 
 
 
 41 
 
4.6 Creating value for customers 
 
Figure 7: Value proposition canvas for sequence-based method 
The value proposition above targets 2 customer groups; Diagnostic Laboratories and NIPH 
(with different customer jobs where indicated). If we focus on one customer group only which 
is the NIPH, we can prove that the customer has certain jobs, pains and gains which our value 
proposition addresses, therefore we have a Problem-Solution fit (Osterwalder et al., 2015). 
Their job is to pay for and cover the cost of AMR testing in order to reduce its spread among 
the populations. They work together with selected laboratories that carry out this AMR testing 
hence they seek to alleviate the pain of having to wait up to 3days for standard culture test and 
poor prescription of antibiotics to patients. They are in need for rapid diagnostic methods that 
will distinguish bacterial from viral infections with results similar to that of standard tests or 
other diagnostic tests. The proposed tool, which is a sequence-based diagnostic method AMR-
Diag, therefore targets to provide a convenient method to detect AMR with accurate results 
within a short time frame at an affordable cost. While providing the ability to store data in a 
data bank that can be used for future analysis. 
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4.7 Estimating the cost of ABR 
ABR poses a significant burden on healthcare systems and national budgets (OECD, 2016). 
In all of 2017 there were 24,199 resistance testings in the Lillehammer Microbiology Lab. 
Half of these tests were done in the Vitek II machine, other half manually with either disk 
diffusion or E-test MIC strips. It takes a technician about 10 mins to carry out a resistance test, 
and Petri dishes with solid agar media cost about 20 NOK each. We can therefore estimate 
that in Lillehammer the cost of ABR testing in the year 2017 was as follows: 
10 mins/test → 241,990 mins → 4033 hours or about 2,5 full time positions 
Assuming a lab technian wage to 400,000 NOK x 1,3 social cost this amounts to 1,5 mill. 
NOK 
Assuming 1sample = 1test and 1 petri dish is used per test, → 20NOK x 12100 = 242,000 
NOK 
Cost of Mueller hinton agar ranges from 187 NOK (100g) – 2,652 NOK (2.5Kg) (Sigma-
aldrich, 2018 ) 
Cost of Antibiotic disks ranges from 148 NOK – 700 NOK (vgdusa, 2018)  
Hospitals spend $10,000-$40,000 on treatment for a patient infected with multidrug resistant 
organism. ABR influences the burden of disease management by increasing Intensive Care 
Unit (ICU) and hospital stays with an additional cost on nursing and medical care. Services 
like food and laundry make up for 13%, lab tests and imaging make up 12%, and pharmacy 
services correspond to <2% of additional costs (OECD, 2016).  
It is easy to see that the days in the hospital treating the patient is the serious cost element. For 
every day saved in hospital care a good and improved test is paid back many times. Even one 
day saved in hospital treatment will be a fantastic saving for the society. The problem is that 
the hospitals get the big bill and diagnostic labs/the primary health care can reduce the cost. 
How can this be insentivised? Simply by the rate paid from the National Health Care system 
to the labs and the health care professionals.  
 43 
The implication of this is that NIPH is a crucial decision maker for getting a new method being 
developed and used. They can set a policy that will make this a success for the company. This 
is also a good argument for implementing this first in Norway and then taking it from country 
to country in the western world first. 
4.8 Competitive analysis 
Considering that sequencing costs about 1000 NOK per sample, and exploiting other factors 
such as speed, convenienc, data storage and sharing, automation and nature of sequencing 
could be some of the factors that make the proposed tool stand out in comparison with standard 
culture and PCR-based methods as shown below. Sequencing prices are continously dropping 
and the proposed tool though expensive when compared to PCR-based and standard culture 
methods, could be affordable upon incentivisation. The proposed tool therefore, stands out 
interms of data storage and sharing, automation and speed since its sequencing is culture-free 
thereby saving the 3-4 days or more of culturing the bacteria. This could be seen as a 
competitive advantage that makes the proposed tool stand out from other methods thereby, 
reducint the risk of immediate competition. 
 
Figure 8: competitive analysis of proposed tool 
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PCR methods Culture on selective media Proposed sequence tool
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The AMR-Diag method is a rapid method and it also generates digital data that can be stored 
in a biobank for later use or continuous monitoring. This means that the method in a way has 
two possible customers, first the doctor/hospital that treats a patient and secondly NIPH that 
has a desired need for continuous monitoring of AMR in Norway. This means that payment 
for the test could be a shared cost between those treating the patient and NIPH monitoring and 
setting guidelines for AMR in Norway.  
From the SWOT analysis, the following suggestions on how the company can  take advantage 
of it strengths and the opportunities in the market to grow and succeed, how it can improve its 
weaknesses and tackle the threats is shown in the confrontational mix below. 
 
Table 7: confrontational mix 
 Strengths 
-there is a dire need for diagnostic test 
-AMR-Diag can be patented 
-available funding from Innovation 
Norway 
-competent team 
 
Weaknesses 
-start up with no brand yet 
-small market size in Norway 
-concept in progress 
-limited flexibility in pricing 
-genotypic method with no measurable 
susceptibility  
Opportunities 
-key partnership with diagnostic labs 
-ability to expand market opportunities 
- growing spread of ABR 
-rarity of sequence-based methods for 
ABR diagnostics 
SO strategies 
• Collaborate with NIPH to 
implement method in use 
• Contract with well know 
laboratories and policy makers 
to raise awareness on the 
importance of diagnostic tests 
• Expand facility for greater 
output 
WO strategies 
• Partner with other market leaders to 
gain market recognition 
• Organise conferences, seminars and 
workshops to create awareness in the 
population on the need for diagnostic 
testing 
Threats 
-competition from other diagnostic 
tests 
-economic risks 
ST strategies 
• Use customer loyalty and 
superior quality to outperform 
competitors 
WT strategies 
• Develop a detection method to provide 
results in the shortest timeframe 
possible 
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•  Secure a strong customer base 
in Norway before going to 
international markets 
• Convince laboratories to use alongside 
current detection methods to provide 
reliable results 
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5. CONCLUSION AND RECOMMENDATIONS  
5.1 Conclusion  
Our study set out to validate the need and establish early feasibility for the development of 
AMR- Diagnosis. Considering the increasing number and spread on antibiotic resistance, there 
is a need to develop a technology that is fast, cost effective, convenient to use and at an 
affordable price. Considering the fact that clinicians may be conservative to adopting a new 
method which hasn’t been standardized yet, and also the fact that most genotypic methods 
predict resistance only and not susceptibility as well, makes it a little harder for new methods 
to be introduced in routine microbiological laboratories.   
Despite the advances so far, a great need for rapid, point-of-care pathogen-speciﬁc, sensitive, 
and aﬀordable diagnostic test still remains in the lookout for the advancement of clinical 
management, infection control, and improved public health response to emerging pathogens 
and antibacterial resistance. The proposed tool AMR-Diag is a leap forward in the fight against 
AMR and therefore should be given a chance to prove what it can do in this course. 
Current Norwegian policy makes use of the EUCAST system for diagnosis which could be a 
hindrance to the proposed tool. Therefore, future policies need to integrate new and innovative 
diagnostic methods for AMR. The true cost of ABR does not only rely on morbidity and 
mortality, but also involves the social perspective. In the event of an outbreak, fatal infectious 
diseases are both scary and expensive to deal with. Countries can choose one of three 
following options to pay for AMR; first, wait until there is a problem and then try to solve it 
as in the case of disease outbreaks. Second, recognize that prevention is better than cure and 
individually invest in the tools needed to fight resistance. Or third, by working together and 
jointly paying for global public goods to efficiently and effectively avoid large-scale outbreak 
of untreatable infections (Resistance, 2016). 
The cost of DNA sequencing is a major obstacle for the proposed tool, AMR-Diag, to become 
implemented. However, the cost of DNA sequencing is expected to continue to be reduced. 
New methods are being implemented that will speed up the use of sequencing as a core tool 
in diagnostics and other fields. As for many important changes in society, a political decision 
is needed for implementing a publically funded monitoring program for AMR. 
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5.2 Recommendations 
Upon completion of our study, we came up with the following proposals to the company with 
proposed tool (AMR-Diag) for further research: 
1. The company with its partners e.g. Hedmark Kunnskapspark, Innlandsykehuset and 
maybe Helse Sørøst should join forces and do political lobbying for Norway to take a 
leading role in combating AMR. This could both benefit the Norwegian health care 
and put Norway in a leading role internationally. We would argue for a 10 year 
program to build up an AMR biobank and a novel diagnostic procedure that can be 
implemented both in human and veterinary medicine. This program could cover at 
least 60-70% of the testing cost in the initial 10-years period, the other cost (30-40%) 
should be covered by the patient treatment refund system. It may even be possible to 
think 80-20. Our prediction is that sequencing over this period of 10 yrs will become 
affordable for the diagnostic test to be paid for by the health care systems around the 
world, and after these 10 yrs Norway will sit on a unique biobank that can be 
commercially exploited. 
2. The company should use Norway as its starting market (beachhead) and then later 
expand the business idea to other countries. 
3.  More research on the true cost estimates of antibacterial resistance should be carried 
out in collaboratioin with “Helsedirektorat” for access to country data. 
4. To create awareness in potential customers through organization of seminars, 
symposiums and workshops on the usage, importance and efficiency of the proposed 
tool, AMR-Diag.  
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